Table 1.
Characteristics of patients and healthy donors.
| Patient Characteristic | HD (n = 19) | SMM (n = 7) | ND (n = 17) | RR (n = 23) | pSCT (n = 14) |
|---|---|---|---|---|---|
| Age, median (range) | 63 (40–91) | 69 (47–78) | 65 (40–82) | 62 (36–86) | 61 (41–74) |
| MM isotype, % IgG/IgA/Light chain only |
- | 86/14/0 | 53/35/12 | 52/17/26 | 64/0/36 |
| High risk cytogenetics * | - | 29% | 56% | 67% | 56% |
| Extramedullary disease, % Present/Absent/Unknown |
- | 0/100/0 | 18/53/29 | 39/48/13 | 14/79/7 |
| Prior lines **, median (range) | - | - | - | 5 (1–10) | 1 (1–2) |
| Prior Lenalidomide, % | - | - | - | 100% | 57% |
| Prior Thalidomide, % | - | - | - | 35% | 0% |
| Prior Pomalidomide, % | - | - | - | 61% | 0% |
| Prior Bortezomib, % | - | - | - | 96% | 100% |
| Prior Carfilzomib, % | - | - | - | 74% | 0% |
| Prior daratumumab, % | - | - | - | 4% | 0% |
| Prior cyclophosphamide, % | - | - | - | 83% | 57% |
| Prior Dexamethasone, % | - | - | - | 100% | 100% |
| Prior SCT, % | - | - | - | 74% | 100% |
| Absolute Lymphocyte Count (×103/µL), median (range) |
- | 1.47 (0.49–3.77) |
1.84 (0.70–3.60) |
0.6 (0.2–2.6) |
0.94 (0.34–3.44) |
* Includes t(4;14), t(14;16), t(14;20), gain 1q, loss 1p, del 17p, complex karyotype. ** Lines of therapy determined as per International Myeloma Working Group criteria. HD = healthy donor; ND = newly diagnosed; pSCT = post-autologous stem cell transplant; RR = relapsed/refractory; SMM = smoldering multiple myeloma.